Jefferies Raises PT On LMNX To $17

Jefferies has raised its price target on Luminex Corp. LMNX from $16 to $17 in light of 1Q11 results. Says Jefferies, in its report, “LMNX's 1Q11 EPS of $0.11 was $0.05 ahead of consensus on stronger revenue growth and profit trends. We are raising our 2011 EPS forecast to $0.30 (from $0.27). Our PT moves to $17 (from $16) on higher cash flow forecasts…LMNX's 1Q11 EPS of $0.11 eclipsed our $0.06 forecast on better than expected revenue trends that flowed at attractive incremental operating margins (45% vs. our 25%). We are raising our 2011 EPS forecast to $0.30 (from $0.27) to account for the 1Q11 upside, tempered somewhat by expectations for higher R&D outlays over the coming periods.” Jefferies maintains its Hold rating on the stock. LMNX closed yesterday at $19.85.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareJefferies & Co.Life Sciences Tools & ServicesLuminex Corp.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!